Rigel Pharmaceuticals Ownership | Who Owns Rigel Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Rigel Pharmaceuticals Ownership Summary


Rigel Pharmaceuticals is owned by 88.13% institutional investors, 3.07% insiders, and 8.81% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 9.83% of RIGL shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 4.27% of its assets in Rigel Pharmaceuticals shares.

RIGL Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockRigel Pharmaceuticals88.13%3.07%8.81%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de1.77M9.83%$47.83M
Armistice capital1.28M7.12%$34.61M
State street1.12M6.23%$30.29M
Vanguard group1.04M5.76%$44.48M
Acadian asset management666.43K3.71%$18.01M
Lsv asset management601.51K3.34%$16.27M
Marshall wace, llp598.38K3.33%$16.18M
Capitolis liquid global markets591.55K3.31%$16.76M
American century companies544.43K3.03%$14.72M
D. e. shaw445.68K2.48%$12.05M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Cm management235.00K5.31%$6.35M
Globeflex capital l p217.84K0.89%$5.89M
Empire financial management company76.44K0.71%$3.27M
Armistice capital1.28M0.62%$34.61M
Watershed asset management16.39K0.46%$443.05K
Range financial group39.50K0.36%$1.07M
Pharvision advisers20.52K0.33%$581.39K
Opaleye management70.00K0.25%$1.89M
Inspire investing63.89K0.14%$1.73M
Capitolis liquid global markets591.55K0.13%$16.76M

Top Buyers

HolderShares% AssetsChange
Armistice capital1.28M0.62%444.00K
American century companies544.43K0.01%289.94K
Acadian asset management666.43K0.03%172.82K
Two sigma investments, lp405.81K0.01%134.58K
Vanguard fiduciary trust124.01K0.00%124.01K

Top Sellers

HolderShares% AssetsChange
Blackrock---14.80M
Nuveen asset management---3.22M
Healthcare of ontario pension plan trust fund---1.36M
Stonepine capital management---1.04M
Soleus capital management10.00K0.01%-290.03K

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust124.01K0.00%124.01K$3.35M
Burney co/91.68K0.08%91.68K$2.48M
Empowered funds82.62K0.01%82.62K$2.23M
Axa investment managers32.59K0.00%32.59K$923.39K
Vanguard global advisers25.81K0.00%25.81K$697.98K

Sold Out

HolderChange
Srs capital advisors-1.00
Financial consulate-10.00
Synergy asset management-15.00
Strategic investment solutions, inc. /il-25.00
Daiwa securities group-40.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026152-20.42%15,851,405-1.52%881.11%84-24.32%43-30.65%
Dec 31, 202545-73.53%2,395,282-84.02%130.19%33-68.27%9-80.43%
Sep 30, 202548-61.29%2,467,259-82.23%130.23%24-61.90%14-61.11%
Jun 30, 20251230.82%13,882,606-0.14%771.27%62-3.13%36-5.26%
Mar 31, 20253-97.60%1,156,951-90.41%60.14%1-98.78%1-95.24%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF790.00K4.27%-7.80K
Vanguard US Total Market Shares ETF548.78K3.07%-
Avantis US Small Cap Value ETF548.48K2.96%-
Vanguard Total Stock Mkt Idx Inv542.05K2.93%-
iShares Russell 2000 ETF421.65K2.28%3.57K
SPDR® S&P Biotech ETF223.01K1.24%500.00
Nuveen Quant Small Cap Equity R6213.85K1.16%-
Vanguard Institutional Extnd Mkt Idx Tr205.46K1.11%972.00
GS Glb Sm Cp CORE Eq Base Inc USD Close197.11K1.07%-93.07K
GS Global SmallCap CORE Eq Base USD197.11K1.07%-51.03K

Recent Insider Transactions


DateNameRoleActivityValue
May 26, 2026Ali-Jackson Kamil-Sell$72.92K
Feb 20, 2026MOOS WALTER H-Sell$145.44K
Feb 04, 2025Schorno Dean L EVP & Chief Financial OfficerSell$42.60K
Feb 05, 2025Schorno Dean L EVP & Chief Financial OfficerSell$38.02K
Feb 04, 2025Santos David A EVP, Chief Commercial OfficerSell$44.46K

Insider Transactions Trends


DateBuySell
2026 Q2-1
2026 Q1-1
2025 Q4--
2025 Q3--
2025 Q2--

RIGL Ownership FAQ


Who Owns Rigel Pharmaceuticals?

Rigel Pharmaceuticals shareholders are primarily institutional investors at 88.13%, followed by 3.07% insiders and 8.80% retail investors. The average institutional ownership in Rigel Pharmaceuticals's industry, Biotech Stocks , is 35.75%, which Rigel Pharmaceuticals exceeds.

Who owns the most shares of Rigel Pharmaceuticals?

Rigel Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (1.77M shares, 9.83%), Armistice capital (1.28M shares, 7.12%), and State street (1.12M shares, 6.23%). Together, they hold 23.18% of Rigel Pharmaceuticals’s total shares outstanding.

Does Blackrock own Rigel Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of Rigel Pharmaceuticals.

Who is Rigel Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Cm management is Rigel Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 5.31% of its assets in 235K Rigel Pharmaceuticals shares, valued at 6.35M$.

Who is the top mutual fund holder of Rigel Pharmaceuticals shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Rigel Pharmaceuticals shares, with 4.27% of its total shares outstanding invested in 790K Rigel Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools